AAPL 173.3301 -0.0979% MSFT 394.89 -1.8297% GOOG 165.942 -1.1662% GOOGL 164.19 -1.1797% AMZN 179.055 -1.0527% NVDA 867.49 -1.1486% META 430.82 -0.4161% TSLA 183.85 -5.2564% TSM 137.87 -0.4549% LLY 772.96 4.8508% V 269.96 -0.6916% AVGO 1316.1583 -1.678% JPM 192.55 -0.3777% UNH 483.25 -1.1819% NVO 127.8 0.7251% WMT 59.34 -1.494% LVMUY 164.99 -1.1918% XOM 118.69 -0.794% LVMHF 825.0 -1.6042% MA 452.83 -0.9342%
VBI Vaccines Inc
Headquartered in Cambridge (Massachusetts), VBI Vaccines Inc (NASDAQ: VBIV) is a Biopharmaceutical Company, which develops vaccine candidates for fighting infectious diseases, such as cytomegalovirus, hepatitis B, and coronaviruses, and glioblastoma.
Investment Rationale – Speculative Buy at USD 2.71
Risk Assessments
Recent News
12 April 2021: VBIV affirmed that the Phase 1b/2a study of Hepatitis B Immunotherapeutic Candidate demonstrated T cell responses in more than or equals to 50% of evaluable patients, while the VBI-2601 (therapeutic vaccine candidate) was well-tolerated in both low and high dose levels.
Financial Highlights for the year ended 31 December 2020 (as on 2 March 2021)
(Source: Company Website)
One Year Share Price Chart
(Source: Refinitiv, Thomson Reuters)
Conclusion
Given the significant unmet medical need of GBM (Glioblastoma Management), therapeutic HBV space and Covid-19 vaccine space, the Company has great potential for future growth. Moreover, the Company has invested heavily in R&D, which may bring additional pipeline candidates and other vaccine opportunities. Furthermore, the progress of Hepatitis B immunotherapeutic candidate shown in recent Phase 1b/2a study is boosting the confidence of the Company. The stock made a 52-week High and Low of USD 6.93 and USD 1.02, respectively.
Based on the operational achievement and business capabilities, we have given a “Speculative Buy” stance on VBI Vaccines Inc at the closing price of USD 2.71 (as on 16 April 2021).
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a biotechnology entity that develops small molecule drugs for cancer, virus, and autoimmune-related diseases.
Investment Rationale – Speculative Buy at USD 3.58
Risk Assessments
Recent News
13 April 2021: RIGL unveiled positive results of Phase 2 trial of fostamatinib in hospitalized patients with COVID-19.
7 April 2021: RIGL announced the closing of its licence agreement with Eli Lilly and Company, whereby it will receive US$125 million as upfront cash payment for supporting Rigel's RIP1 inhibitor program.
Financial Highlights for the year ended 31 December 2020 (as 2 March 2021)
(Source: Company Website)
One Year Share Price Chart
(Source: Refinitiv, Thomson Reuters)
Valuation Methodology: EV/Sales Approach (NTM) (Illustrative)
Conclusion
Rigel’s phase 2 clinical trial established significant progress for the Covid-19 drug development in extreme cases, which boosted the investor sentiments. Moreover, the FY20 results demonstrated a considerable decline in net loss per share with improved revenue generation. Adjacently, the annual price increase of TAVALISSE shall support the Company’s growth in the future as well. However, there are uncertainties in the short-term as patient-doctor interactions and fewer patient visits during Covid-19 conditions can impact business performance. However, the Company has substantial financial resources to navigate through this challenging phase and manage its project funding requirement and create a significant value for shareholders. The stock made a 52-week High and Low of USD 5.50 and USD 1.45, respectively.
Based on the positive Phase 2 clinical trial (fostamatinib), improved financials, business capabilities and valuation conducted above, we have given a “Speculative Buy” stance on Rigel Pharmaceuticals Inc at the closing price of USD 3.58 (as on 16 April 2021), with a lower double-digit upside potential based on 4.80x EV/NTM Sales (approx.) on FY21E Sales (approx.).
*All forecasted figures and Peer/Industry Information have been taken from Refinitiv, Thomson Reuters.